Sanofi
10% owner at Latigo Biotherapeutics, Inc. (LTGO) since August 2026
Sanofi has filed 9 insider reports with the SEC since July 2021, as 10% owner at Latigo Biotherapeutics, Inc. (LTGO), 10% owner at Attovia Therapeutics, Inc. (ATTO) and 10% owner at MeiraGTx Holdings plc (MGTX) and at 2 more companies. In the last 12 months Sanofi bought $5.1M of stock on the open market. The latest filing, on August 12, 2026, reports conversion of a derivative at Latigo Biotherapeutics, Inc. (LTGO).
Schedule 13D and 13G filings by Sanofi
- 2026-05-06AGMB SCHEDULE 13G filed by AgomAb Therapeutics NVSchedule 13G
- 2025-04-29IPHA SCHEDULE 13G filed by Innate Pharma S.A. ADSSchedule 13G
- Filings
- 9
- Companies
- 5
- Bought on market
- $2.74B
- Sold on market
- None
Companies where Sanofi is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| 10% ownersince August 2026 | $13.24 | Aug 12, 2026 | |||||
| 10% ownersince August 2026 | $5.1M | $17.00 | $15.58-8.4% | Aug 7, 2026 | |||
| 10% ownersince August 2024 | $8.14 | Aug 13, 2024 | |||||
| 10% ownersince August 2021 | 75,668,031 | $2.74B | $38.00 | Sep 14, 2021 | |||
| 10% ownersince July 2021 | $1M | $15.00 | $46.06+207% | Aug 3, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Aug 10, 2026LTGOLarge owner Sanofi converted options into 672,778 sharesForm 4Conversion of a derivative
- Aug 6, 2026LTGOSanofi became an insiderForm 3New insider
- Aug 6, 2026+$5.1MATTOLarge owner Sanofi converted options into 782,855 shares and bought $5,100,000 worth of shares (300,000 units at $17.00)Form 4Conversion of a derivativeOpen-market purchase
- Aug 4, 2026ATTOSanofi became an insiderForm 3New insider
- Aug 12, 2024MGTXNew insider Sanofi claimed ownership of 12,197,737 units of Ordinary SharesForm 3New insider
- Sep 14, 2021+$2.74BTBIOSEC Form 4: Sanofi bought $2,735,376,686 worth of Common Stock (71,983,597 units at $38.00), increasing direct ownership by 1,954% to 75,668,031 unitsForm 4Open-market purchase
- Aug 2, 2021TBIOSEC Form 3: Sanofi claimed ownership of 3,684,434 units of Common StockForm 3New insider
- Aug 2, 2021+$1MSNYSEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)Form 4Conversion of a derivativeOpen-market purchase
Compare Sanofi with
- Sanofi vs Neha Krishnamohan1 shared
- Sanofi vs Alexandria Forbes1 shared
- Sanofi vs Alan Sebulsky1 shared
- Sanofi vs Richard Giroux1 shared
- Sanofi vs Stuart Naylor1 shared
- Sanofi vs Robert K Zeldin1 shared
Other insiders at the same companies
- Neil SinglaLTGO
- Neha KrishnamohanLTGO
- Todd N SmithLTGO
- Alexandria ForbesMGTX
- Alan SebulskyMGTX
- Goldman Sachs Group IncATTO
- Richard GirouxMGTX
- Stuart NaylorMGTX
- Robert K ZeldinMGTX
- Robert J WollinMGTX
- Debra YuMGTX
- Thomas E ShenkMGTX
- Nicole SeligmanMGTX
- Neil MendozaMGTX
- Ellen HukkelhovenMGTX
- Keith R. HarrisMGTX
Questions about Sanofi
- What is Sanofi's role at Latigo Biotherapeutics, Inc.?
- Sanofi reports to the SEC as 10% owner at Latigo Biotherapeutics, Inc. (LTGO), according to the latest filing on August 12, 2026. Sanofi has also filed as 10% owner at Attovia Therapeutics, Inc. (ATTO), 10% owner at MeiraGTx Holdings plc (MGTX), 10% owner at Translate Bio, Inc. (TBIO) and 10% owner at Icosavax, Inc. (SNY).
- How many shares does Sanofi own?
- After the latest filing that states it, Sanofi directly owned 75,668,031 shares of Translate Bio, Inc. (TBIO). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Sanofi bought or sold stock recently?
- The most recent open-market purchase was on August 6, 2026: bought 300,000 shares of Attovia Therapeutics, Inc. (ATTO) for $5.1M at an average of $17.00.
- How do I get alerts when Sanofi files?
- Follow Sanofi on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Sanofi (SEC CIK 0001121404). Totals count each trade once, skipping amendments whose original is on file, from Jul 29, 2021 on. View on SEC EDGAR · Get this as JSON